PV Bulletin

MHRA: Updated information on the MHRA's service providing scientific and regulatory guidance to developers of innovative medical products

Guidance for innovators and developers on accessing regulatory support and scientific expertise.

Primary source: Medicines and Healthcare products Regulatory Agency (MHRA)

PV Impact Brief

MonitoringConfidence: high

What changed

Updated guidance on the MHRA Innovation Accelerator, emphasizing access to regulatory support and scientific expertise for early-stage engagement with the regulator.

Why it matters

This initiative allows innovators and developers to engage proactively with MHRA on pharmacovigilance planning and risk management, potentially improving product safety and regulatory adherence early in development.

Action needed

Innovators must now utilize the Innovation Accelerator for access to regulatory expertise and guidance on pharmacovigilance and risk management strategies.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Guidance
Policy status
revised
Publication date
2026-06-29
Policy change
Updated information on the MHRA's service providing scientific and regulatory guidance to developers of innovative medical products.

Key changes

Consolidated pathway for early-stage engagement with the regulator for innovative medicines and medical devices, focusing on scientific and regulatory advice.

Affected workflows

Country Compliance

Responsible groups

Clinical DevelopmentSafety TeamsRegulatory Affairs

PV impact

Facilitates proactive discussion with regulators on pharmacovigilance planning and risk management strategies early in the product development lifecycle for innovative products.

View regulator source

Source document details

Exact policy details

Innovation Accelerator Access
Access to MHRA scientific expertise and regulatory guidance
Applies to: Innovators and developers of innovative products
The Innovation Accelerator provides innovators and developers of innovative products access to MHRA scientific expertise, regulatory guidance and an enhanced advice and signposting service. · p. 1 · High · Source
Supporting ILAP
Supports the delivery of the Innovative Licensing and Access Pathway (ILAP)
Applies to: Part of the regulatory framework for innovative medical products
It also supports the delivery of the Innovative Licensing and Access Pathway (ILAP). · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jun 29, 2026

Full briefing

Practical implication

Innovators must now utilize the Innovation Accelerator for access to regulatory expertise and guidance on pharmacovigilance and risk management strategies.

The MHRA Innovation Accelerator provides a consolidated pathway for early-stage engagement with the regulator and offers scientific and regulatory guidance to developers of innovative medical products, facilitating discussion on pharmacovigilance and risk management strategies.

What changed: Updated guidance on the MHRA Innovation Accelerator, emphasizing access to regulatory support and scientific expertise for early-stage engagement with the regulator.

Why it matters: This initiative allows innovators and developers to engage proactively with MHRA on pharmacovigilance planning and risk management, potentially improving product safety and regulatory adherence early in development.

Practical implication: Innovators must now utilize the Innovation Accelerator for access to regulatory expertise and guidance on pharmacovigilance and risk management strategies.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Medicines and Healthcare products Regulatory Agency (MHRA)#revised#policy-change#Guidance#firecrawl-policy-agent#United Kingdom

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward